ライフサイエンスコーパス: erythema migrans

1 t negative association between arthritis and erythema migrans.

2 ents with early Lyme disease associated with erythema migrans.

3 anifestation, however, in both continents is erythema migrans.

4 lin was found to be an effective regimen for erythema migrans.

5 x patients subsequently had a new episode of erythema migrans.

6 ed with longer illness duration and multiple erythema migrans.

7 eatment-matched immunocompetent persons with erythema migrans.

8 a large (>/=5-cm diameter) rash, known as an erythema migrans.

9 ents after completing antibiotic therapy for erythema migrans.

10 s with early Lyme disease who presented with erythema migrans.

11 Lyme disease was defined by the presence of erythema migrans.

12 received standard courses of antibiotics for erythema migrans.

13 among adult European patients with solitary erythema migrans.

14 d from patients with consecutive episodes of erythema migrans.

15 re evaluated in adult European patients with erythema migrans.

16 hly sensitive by itself for the diagnosis of erythema migrans.

17 ination characteristics for the diagnosis of erythema migrans.

18 nhance therapeutic efficacy in patients with erythema migrans.

19 ies to B. burgdorferi in patients with acute erythema migrans.

20 h a compatible clinical syndrome but without erythema migrans.

21 and 42 adult patients with culture-confirmed erythema migrans.

22 ents with early Lyme disease associated with erythema migrans.

23 ents with early Lyme disease associated with erythema migrans.

24 86 antibiotic-treated European patients with erythema migrans, 45 with post-Lyme symptoms and 41 with

25 lness, a median of 4 days after the onset of erythema migrans, 51% of the patients had proliferative

26 lar pain (100%), sleep disturbances (75.3%), erythema migrans (59.7%), headache (46.8%), fatigue (44.

27 burgdorferi at the time of presentation with erythema migrans (65%) and at the time of relapse (57%).

28 lantation of skin biopsies taken from rabbit erythema migrans (a uniquely rich source of B. burgdorfe

29 n subjects with Lyme disease presenting with erythema migrans alone (n=36), erythema migrans with neu

30 Among the 27 patients who had erythema migrans alone with no associated signs or sympt

31 e due to failure to recognize early disease (erythema migrans) among African Americans, resulting in

32 s, skin biopsy samples from 42 patients with erythema migrans and 27 patients with acrodermatitis chr

33 symptoms was compared between patients with erythema migrans and 81 control subjects without a histo

34 confirmed early LD, based on the presence of erythema migrans and documentation of seroconversion or

35 course of oral doxycycline for treatment of erythema migrans and for a 14-day course for treatment o

36 etween the White to African American IRR for erythema migrans and for Lyme disease-associated arthrit

37 mples from 39 culture-positive patients with erythema migrans and in 20 healthy control subjects.

38 ng Whites: IRR = 5.7 (95% CI: 2.4, 13.9) for erythema migrans and IRR = 0.7 (95% CI: 0.4, 1.1) for ar

39 5 consecutive patients with the diagnosis of erythema migrans and reported original data regarding th

40 variability in the clinical presentation of erythema migrans and the need to factor in multiple comp

41 Patients with erythema migrans and underlying hematological malignancy

42 sitive patients with Lyme disease-associated erythema migrans and were evaluated for an association w

43 chetemia explain why untreated patients with erythema migrans are at risk for dissemination of B. bur

44 Lyme disease patients with erythema migrans are said to have post-treatment Lyme di

45 Blood was obtained from patients with erythema migrans before (n = 29) and 2 months after (n =

46 from 17 patients who received a diagnosis of erythema migrans between 1991 and 2011 and who had 22 pa

47 ous isolates of B. burgdorferi, 22 blood and erythema migrans biopsy isolates from Lyme disease patie

48 p35 and p37 mRNA were detected in erythema migrans biopsy specimens from 2 patients and in

49 d sensitivities of 63% for culture-confirmed erythema migrans cases and 92% for later stages, as comp

50 Early erythema migrans commonly had homogeneous or central red

51 Erythema migrans developed at the site of the tick bite

52 Erythema migrans developed more frequently after untreat

53 ive for B. burgdorferi DNA in a patient with erythema migrans early during therapy and in a patient w

54 ri DNA in skin samples from 90 patients with erythema migrans (EM) and in synovial fluid (SF) from 63

55 unch biopsy specimens during each episode of erythema migrans (EM) and was subjected to molecular str

56 me of intradermal inoculation to the time of erythema migrans (EM) development (approximately 7 days

57 ic-treated patients, 53% with culture-proven erythema migrans (EM) had IgG responses to recombinant g

58 fection causes an initial skin lesion called erythema migrans (EM) in human Lyme disease and in model

59 in 25 of 26 patients with early seronegative erythema migrans (EM) LD; 105 of 107 patients with serop

60 elia burgdorferi spreads in the skin to form erythema migrans (EM) lesions and then disseminates to o

61 hese inflammatory responses in patients with erythema migrans (EM) or Lyme arthritis (LA) to elucidat

62 Case-patients with erythema migrans (EM) rash >/=5 cm were recruited from t

63 l manifestation of early Lyme disease is the erythema migrans (EM) skin lesion that develops at the t

64 allel, analyzed B. burgdorferi isolates from erythema migrans (EM) skin lesions in 91 patients, and c

65 urgdorferi genotypes have been isolated from erythema migrans (EM) skin lesions in patients with Lyme

66 bjective was to obtain data on patients with erythema migrans (EM) who have symptoms/signs suggesting

67 n patients with Lyme disease associated with erythema migrans (EM), 115 individuals with no other ide

68 to, results in the consistent development of erythema migrans (EM), dermal infection, and visceral di

69 ltiplex assays in the serum of patients with erythema migrans (EM), joint fluid of patients with Lyme

70 stage LD but is insensitive in patients with erythema migrans (EM), the most common manifestation of

71 tients > or = 16 years of age diagnosed with erythema migrans (EM), the rash associated with early Ly

72 rgdorferi in 46 patients with culture-proven erythema migrans (EM).

73 n skin and peripheral blood of patients with erythema migrans (EM).

74 s from the Lyme, Connecticut, region who had erythema migrans, facial palsy, or Lyme arthritis 10-20

75 ent evidence supports treating patients with erythema migrans for no longer than 10 days when doxycyc

76 of the early steps of Borrelia invasion and erythema migrans formation after tick bite.

77 ous dissemination, 104 untreated adults with erythema migrans from a Lyme disease diagnostic center i

78 Twenty of 23 patients with culture-confirmed erythema migrans had a detectable antibody response to C

79 0-day doxycycline treatment in patients with erythema migrans has been assessed in the United States

80 ents with early Lyme disease associated with erythema migrans have a positive blood culture based on

81 We observed erythema migrans in a patient with an attached A. americ

82 Our data show that repeat episodes of erythema migrans in appropriately treated patients were

83 B. lonestari is a probable cause of erythema migrans in humans.

84 f Lyme disease vaccine; 118 participants had erythema migrans in which Borrelia burgdorferi was detec

85 Erythema migrans is the most common manifestation of Lym

86 urteen-day antibiotic treatment, as used for erythema migrans, is effective.

87 Localized Lyme disease, manifested by erythema migrans, is usually treated with oral doxycycli

88 City with early Lyme disease associated with erythema migrans; it is the largest number of borrelial

89 on, 37 percent of the patients with a single erythema migrans lesion and 89 percent of those with mul

90 manifestations of Lyme disease were a single erythema migrans lesion in 66 percent, multiple erythema

91 Lyme disease as either a clinician-diagnosed erythema migrans lesion or a positive standard 2-tiered

92 eld, particularly for patients with a single erythema migrans lesion.

93 4.2%; P = 0.006) and more often had multiple erythema migrans lesions (41.9% vs. 15.0%; P < 0.001) th

94 s were more likely than patients with single erythema migrans lesions (P<0.001) to have a positive an

95 ciation existed for the presence of multiple erythema migrans lesions (P=.045), providing clinical co

96 246 adult patients with erythema migrans lesions at least 5 cm in diameter were

97 lesion and 89 percent of those with multiple erythema migrans lesions had antibodies against Borrelia

98 thema migrans lesion in 66 percent, multiple erythema migrans lesions in 23 percent, arthritis in 6 p

99 Borrelia burgdorferi isolates obtained from erythema migrans lesions or blood of Lyme disease patien

100 sease had to be indicated by either multiple erythema migrans lesions or objective evidence of organ

101 Patients with multiple erythema migrans lesions were more likely than patients

102 activation of pro-inflammatory cytokines in erythema migrans lesions, particularly interferon-gamma,

103 Of 140 patients enrolled, 133 had multiple erythema migrans lesions.

104 e United States are Lyme disease; a Southern erythema migrans-like illness; human monocytic ehrlichio

105 Further studies of erythema migrans-like rashes in the Southern United Stat

106 m was collected from 16 early, predominantly erythema migrans Lyme disease patients with neurologic p

107 dorferi genotypes in cells and patients with erythema migrans or Lyme arthritis.

108 ty of the two-step process for patients with erythema migrans or with later manifestations of Lyme di

109 atients with either early localized disease (erythema migrans) or disseminated disease.

110 Prevention (CDC) serum bank, and a group of erythema migrans patients from whose skin lesions B. bur

111 the frequency of nonspecific symptoms among erythema migrans patients was similar to that among cont

112 In the 15 erythema migrans patients who had associated signs and s

113 18 patients with microbiologically confirmed erythema migrans presented a median of 3 days after symp

114 cells from 27 patients with culture-positive erythema migrans, production of inflammatory cytokines p

115 arious MTTT protocols in patients with acute erythema migrans ranged from 36% (95% confidence interva

116 bite from an Ixodes scapularis tick and the erythema migrans rash associated with Lyme disease.

117 However, the erythema migrans rash may go undetected in children and

118 disease onset, and proportion of cases with erythema migrans rash were within expected limits.

119 2%) of 17 serum samples from persons who had erythema migrans reacted positively by an ELISA with one

120 borreliosis on the basis of the presence of erythema migrans reacted positively in ELISAs with one o

121 White patients were more likely to have erythema migrans (risk ratio = 2.8, 95% CI: 1.9, 4.1) an

122 ly associated with a shorter duration of the erythema migrans skin lesion (P = 0.020), smaller skin l

123 The erythema migrans skin lesion was required for study entr

124 jor ospC groups from ticks, from the primary erythema migrans skin lesion, and from secondary sites,

125 9 (MMP-9) was selectively upregulated in the erythema migrans skin lesions of patients with acute Lym

126 afzelii, or Borrelia garinii recovered from erythema migrans skin lesions of patients with Lyme borr

127 No studies included patients without erythema migrans, so specificity data and likelihood rat

128 determined using serum from 55 patients with erythema migrans; specificity was determined using serum

129 f 42 (21.4%) patients with culture-confirmed erythema migrans tested at the baseline visit, 42 of 118

130 Erythema migrans, the characteristic skin manifestation

131 Among 311 patients with erythema migrans, the frequency of coinfection with HGA

132 patients with culture-confirmed episodes of erythema migrans to distinguish between relapse and rein

133 Concomitant erythema migrans was registered in 104 of 144 patients (

134 Patients with multiple erythema migrans were almost uniformly culture positive

135 one of the 22 paired consecutive episodes of erythema migrans were associated with the same strain of

136 study assessed whether repeated episodes of erythema migrans were due to the same or different strai

137 Skin biopsies of erythema migrans were performed for culture and detectio

138 n 11 (28%) of 39 of subjects presenting with erythema migrans, which increased to 50% at 4 weeks of f

139 t of children with Lyme disease present with erythema migrans, which is an early stage of the disease

140 Erythema migrans, while not pathognomonic, is the most c

141 Similarly, serum samples from patients with erythema migrans who were infected with the RST1 genotyp

142 Adult patients with erythema migrans with a positive skin or blood culture f

143 ed States, Lyme disease commonly presents as erythema migrans with homogeneous or central redness and

144 esenting with erythema migrans alone (n=36), erythema migrans with neurological disease (n=12), and c

145 al and laboratory findings for patients with erythema migrans with regard to the number of Borrelia b

146 s with probable LD, based on the presence of erythema migrans without documented seroconversion or of